Arbutus Biopharma Corp (ABUS) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-10

Arbutus Biopharma Corp (ABUS) has filed 2 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-10. 3 Form 8-K material event filings were reported by ABUS in the last 90 days. InsiderAlpha tracks every ABUS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Arbutus Biopharma Corp (ABUS)

SEC CIK	0001447028

90-Day SEC Filing Activity

Form 4 filings (90d)	2
Form 8-K filings (90d)	3
Latest Form 4 filing	2026-06-10

Recent ABUS Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-02-02	Nguyen Tuan	Chief Financial Officer	A — Grant or award	73.5K	$0.00	—	SEC
2026-02-02	Androski Lindsay	President and CEO	A — Grant or award	28.0K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Arbutus Biopharma Corp (ABUS). Updated in real time as new filings are submitted to the SEC.

Most-Active ABUS Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Sawhney Roger	1	—
Beardsley Robert A	1	—

Recent ABUS Form 8-K Material Events

2026-07-16 — Item 1.02, 5.02, 8.01, 9.01 [SEC]
2026-05-27 — Item 5.02, 5.07, 9.01 [SEC]
2026-05-13 — Item 2.02, 9.01 [SEC]
2026-04-15 — Item 8.01, 9.01 · Clinical · positive [SEC]
The FDA has granted Fast Track designation for Arbutus's imdusiran for the treatment of chronic hepatitis B. Fast Track designation facilitates development and expedites FDA review of investigational therapies for serious conditions with unmet medical need, representing a positiv
2026-03-23 — Item 2.02, 9.01 · Earnings · neutral [SEC]
Arbutus Biopharma Corporation announced its financial results for the fourth quarter and full year ended December 31, 2025. The filing provides standard quarterly and annual financial reporting without indication of beat/miss or guidance changes.

Recent Insider Filings

2026-06-10 — Sawhney Roger (Director)
2026-06-10 — Beardsley Robert A (Director)
2026-02-03 — Nguyen Tuan (Chief Financial Officer)
2026-02-03 — Androski Lindsay (President and CEO)
2025-08-04 — Sawhney Roger (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ABUS insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

ABUS Insider Trading — FAQ

What is the latest insider trade for ABUS?: Arbutus Biopharma Corp (ABUS) had 2 insider filings in the last 90 days, with the most recent on 2026-06-10. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ABUS stock?: 0 insider purchases of ABUS were filed in the last 90 days.
How many insiders are selling ABUS stock?: 0 insider sales of ABUS were filed in the last 90 days.
Where can I see ABUS SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every ABUS SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live ABUS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.